Outcome measures | Mean CBT (± SD) | Mean RPT (± SD) | Mean TAU (± SD) | F-value | P-value | ηp2 | Pairwise comparisons | Cohen's d CBT vs RPT | Cohen's d CBT vs TAU | Cohen's d RPT vs TAU |
---|---|---|---|---|---|---|---|---|---|---|
PCS total score (0 to 52) | ||||||||||
Baseline | 34.13 (9.29) | 32.19 (7.05) | 31.23 (7.18) | |||||||
Posttreatment | 24.79 (7.41) | 31.36 (7.10) | 31.47 (6.90) | 133.34 | 0.001 | 0.63 | 1 < 2, 3 | 0.91 | 0.93 | 0.02 |
Six-month follow-up | 25.50 (7.24) | 30.64 (6.75) | 32.74 (7.04) | 144.33 | 0.001 | 0.65 | 1 < 2 < 3 | 0.73 | 1.01 | 0.30 |
PCS-Rumination (0 to 16) | ||||||||||
Baseline | 11.87 (3.08) | 11.08 (2.57) | 10.92 (2.77) | |||||||
Posttreatment | 8.82 (2.47) | 10.68 (2.53) | 11.09 (2.60) | 100.82 | 0.001 | 0.56 | 1 < 2, 3 | 0.74 | 0.90 | 0.16 |
Six-month follow-up | 9.02 (2.46) | 10.28 (2.50) | 11.34 (2.61) | 87.82 | 0.001 | 0.53 | 1 < 2 < 3 | 0.51 | 0.91 | 0.42 |
PCS-Magnification (0 to 12) | ||||||||||
Baseline | 6.38 (2.63) | 6.23 (2.40) | 5.92 (2.22) | |||||||
Posttreatment | 5.18 (2.27) | 6.15 (2.48) | 6.19 (2.23) | 33.08 | 0.001 | 0.30 | 1 < 2, 3 | 0.41 | 0.45 | 0.02 |
Six-month follow-up | 5.59 (2.32) | 6.34 (2.42) | 6.62 (2.27) | 23.65 | 0.001 | 0.23 | 1 < 2 < 3 | 0.32 | 0.45 | 0.12 |
PCS-Helplessness (0 to 24) | ||||||||||
Baseline | 15.89 (5.07) | 14.89 (3.98) | 14.57 (4.13) | |||||||
Posttreatment | 10.79 (4.04) | 14.55 (3.98) | 14.36 (3.99) | 74.29 | 0.001 | 0.49 | 1 < 2, 3 | 0.94 | 0.90 | 0.05 |
Six-month follow-up | 10.95 (4.01) | 14.02 (3.85) | 14.94 (4.27) | 68.04 | 0.001 | 0.46 | 1 < 2 < 3 | 0.78 | 0.96 | 0.23 |
CPAQ (0 to 120) | ||||||||||
Baseline | 49.00 (10.33) | 44.40 (8.90) | 44.45 (10.80) | |||||||
Posttreatment | 51.30 (9.53) | 43.36 (9.00) | 43.15 (10.86) | 33.07 | 0.001 | 0.29 | 1 > 2, 3 | 0.86 | 0.80 | 0.02 |
Six-month follow-up | 50.46 (9.37) | 43.47 (8.85) | 42.53 (10.40) | 24.97 | 0.001 | 0.24 | 1 > 2, 3 | 0.77 | 0.80 | 0.10 |
HAM-D (0 to 50) | ||||||||||
Baseline | 14.47 (3.93) | 14.94 (4.03) | 14.09 (4.64) | |||||||
Posttreatment | 7.78 (2.46) | 7.98 (1.80) | 8.17 (2.25) | 2.17 | 0.12 | 0.03 | ns | 0.09 | 0.17 | 0.09 |
Six-month follow-up | 7.91 (2.50) | 8.19 (1.96) | 8.57 (2.47) | 4.05 | 0.02 | 0.05 | 1 < 3 | 0.12 | 0.27 | 0.17 |
HARS (0 to 56) | ||||||||||
Baseline | 10.84 (4.27) | 11.22 (3.75) | 9.50 (2.98) | |||||||
Posttreatment | 7.09 (2.96) | 7.11 (2.39) | 7.40 (2.18) | 9.71 | 0.001 | 0.11 | 1, 2 < 3 | 0.01 | 0.12 | 0.13 |
Six-month follow-up | 7.25 (3.02) | 7.39 (2.57) | 7.58 (2.07) | 8.49 | 0.001 | 0.10 | 1, 2 < 3 | 0.05 | 0.13 | 0.08 |
PVAS (0 to 100) | ||||||||||
Baseline | 64.20 (10.78) | 68.13 (9.84) | 64.72 (10.44) | |||||||
Posttreatment | 36.88 (8.29) | 37.14 (10.53) | 38.68 (7.48) | 2.25 | 0.109 | 0.03 | ns | 0.03 | 0.23 | 0.17 |
Six-month follow-up | 40.68 (10.93) | 40.54 (9.61) | 44.34 (8.56) | 7.48 | 0.001 | 0.09 | 2 < 3 | 0.01 | 0.37 | 0.42 |
FIQ (0 to 100) | ||||||||||
Baseline | 65.91 (10.85) | 66.36 (9.88) | 64.48 (10.50) | |||||||
Posttreatment | 46.21 (9.18) | 50.93 (9.38) | 48.64 (6.77) | 6.96 | 0.001 | 0.08 | 1 < 2, 3 | 0.51 | 0.30 | 0.28 |
Six-month follow-up | 48.80 (9.11) | 52.84 (9.17) | 53.26 (7.54) | 11.22 | 0.001 | 0.12 | 1 < 2, 3 | 0.44 | 0.53 | 0.05 |
EuroQol VAS (0 to 100) | ||||||||||
Baseline | 44.55 (16.47) | 46.82 (15.62) | 43.87 (14.50) | |||||||
Posttreatment | 60.45 (16.63) | 58.00 (13.07) | 53.49 (14.40) | 11.49 | 0.001 | 0.13 | 1 > 2, 3 | 0.16 | 0.45 | 0.33 |
Six-month follow-up | 58.39 (16.27) | 56.73 (13.85) | 52.26 (14.03) | 10.44 | 0.001 | 0.12 | 1 > 2, 3 | 0.11 | 0.40 | 0.32 |